{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T19:41:42Z","timestamp":1794426102199,"version":"4.9.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T00:00:00Z","timestamp":1588550400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T00:00:00Z","timestamp":1588550400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Central nervous system (CNS) spreading from epithelial ovarian carcinoma (EOC) is an uncommon but increasing phenomenon. We previously reported in a small series of 11 patients a correlation between Androgen Receptor (AR) loss and localization to CNS. Aims of this study were: to confirm a predictive role of AR loss in an independent validation cohort; to evaluate if AR status impacts on EOC survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We collected an additional 29 cases and 19 controls as validation cohort. In this independent cohort at univariate analysis, cases exhibited lower expression of AR, considered both as continuous (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009\u00a00.001) and as discrete variable (10% cut-off:\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009\u00a00.003; Immunoreactive score:\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009\u00a00.001). AR negative EOC showed an odds ratio (OR)\u2009=\u20098.33 for CNS dissemination compared with AR positive EOC. Kaplan-Meier curves of the combined dataset, combining data of new validation cohort with the previously published cohort, showed that AR\u2009&lt;\u2009\u00a010% significantly correlates with worse outcomes (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005 for Progression Free Survival (PFS) and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002 for brain PFS (bPFS) respectively).\n                    <\/jats:p>\n                    <jats:p>Comparison of AR expression between primary tissue and paired brain metastases in the combined dataset did not show any statistically significant difference.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We confirmed AR loss as predictive role for CNS involvement from EOC in an independent cohort of cases and controls. Early assessment of AR status could improve clinical management and patients\u2019 prognosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13048-020-00655-2","type":"journal-article","created":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T08:03:50Z","timestamp":1588579430000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers"],"prefix":"10.1186","volume":"13","author":[{"given":"Gloria","family":"Mittica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Goia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Gambino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Scotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Fonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Senetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Aglietta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvio","family":"Borella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sapino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dionyssios","family":"Katsaros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furio","family":"Maggiorotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Ghisoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Giannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Tuninetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Genta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Eusebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Momi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Cassoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Valabrega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,4]]},"reference":[{"key":"655_CR1","doi-asserted-by":"crossref","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence andmortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","DOI":"10.3322\/caac.21492"},{"issue":"7","key":"655_CR2","doi-asserted-by":"publisher","first-page":"C444","DOI":"10.1152\/ajpcell.00188.2015","volume":"309","author":"TL Yeung","year":"2015","unstructured":"Yeung TL, Leung CS, Yip KP, Au Yeung CL, Wong ST, Mok SC. Cellular and molecular processes in ovarian cancer metastasis. A review in the theme: cell and molecular processes in cancer metastasis. Am J Physiol Cell Physiol. 2015;309(7):C444\u201356.","journal-title":"Am J Physiol Cell Physiol"},{"key":"655_CR3","first-page":"527453","volume":"2011","author":"E Piura","year":"2011","unstructured":"Piura E, Piura B. Brain metastases from ovarian carcinoma. ISRN Oncol. 2011;2011:527453.","journal-title":"ISRN Oncol"},{"issue":"3","key":"655_CR4","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.ygyno.2018.06.022","volume":"150","author":"K Deng","year":"2018","unstructured":"Deng K, Yang C, Tan Q, Song W, Lu M, Zhao W, et al. Sites of distant metastases and overall survival in ovarian cancer: a study of 1481 patients. Gynecol Oncol. 2018;150(3):460\u20135.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"655_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ygyno.2011.12.438","volume":"125","author":"YC Chiang","year":"2012","unstructured":"Chiang YC, Qiu JT, Chang CL, Wang PH, Ho CM, Lin WC, et al. Brain metastases from epithelial ovarian carcinoma: evaluation of prognosis and managements - a Taiwanese gynecologic oncology group (TGOG) study. Gynecol Oncol. 2012;125(1):37\u201341.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"655_CR6","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1200\/JCO.2002.20.4.982","volume":"20","author":"DF Kolomainen","year":"2002","unstructured":"Kolomainen DF, Larkin JM, Badran M, A'Hern RP, King DM, Fisher C, et al. Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidence. J Clin Oncol. 2002;20(4):982\u20136.","journal-title":"J Clin Oncol"},{"issue":"5","key":"655_CR7","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1097\/IGC.0b013e318216cad0","volume":"21","author":"G Cormio","year":"2011","unstructured":"Cormio G, Loizzi V, Falagario M, Calace A, Colamaria A, De Tommasi A, et al. Central nervous system metastases from epithelial ovarian cancer: prognostic factors and outcomes. Int J Gynecol Cancer. 2011;21(5):816\u201321.","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"655_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-014-1447-9","volume":"119","author":"S Pakneshan","year":"2014","unstructured":"Pakneshan S, Safarpour D, Tavassoli F, Jabbari B. Brain metastasis from ovarian cancer: a systematic review. J Neuro-Oncol. 2014;119(1):1\u20136.","journal-title":"J Neuro-Oncol"},{"issue":"2","key":"655_CR9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ygyno.2012.11.001","volume":"128","author":"K Nasu","year":"2013","unstructured":"Nasu K, Satoh T, Nishio S, Nagai Y, Ito K, Otsuki T, et al. Clinicopathologic features of brain metastases from gynecologic malignancies: a retrospective study of 139 cases (KCOG-G1001s trial). Gynecol Oncol. 2013;128(2):198\u2013203.","journal-title":"Gynecol Oncol"},{"key":"655_CR10","doi-asserted-by":"crossref","unstructured":"Marchetti C, Ferrandina G, Cormio G, Gambino A, Cecere S, Lorusso D, et al. Brain metastases in patients with EOC: Clinico-pathological andprognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19). Gynecol Oncol. 2016;143:532-8.","DOI":"10.1016\/j.ygyno.2016.09.025"},{"issue":"8","key":"655_CR11","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1097\/IGC.0000000000001341","volume":"28","author":"JW Kwon","year":"2018","unstructured":"Kwon JW, Yoon JH, Lim MC, Joo J, Yoo H, Shin SH, et al. Treatment results and prognostic factors of brain metastases from ovarian cancer: a single institutional experience of 56 patients. Int J Gynecol Cancer. 2018;28(8):1631\u20138.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"655_CR12","first-page":"125","volume":"36","author":"IG Tkalia","year":"2014","unstructured":"Tkalia IG, Vorobyova LI, Svintsitsky VS, Nespryadko SV, Goncharuk IV, Lukyanova NY, et al. Clinical significance of hormonal receptor status of malignant ovarian tumors. Exp Oncol. 2014;36(2):125\u201333.","journal-title":"Exp Oncol"},{"issue":"3","key":"655_CR13","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.ygyno.2015.06.032","volume":"138","author":"M van Kruchten","year":"2015","unstructured":"van Kruchten M, van der Marel P, de Munck L, Hollema H, Arts H, Timmer-Bosscha H, et al. Hormone receptors as a marker of poor survival in epithelial ovarian cancer. Gynecol Oncol. 2015;138(3):634\u20139.","journal-title":"Gynecol Oncol"},{"issue":"25","key":"655_CR14","doi-asserted-by":"publisher","first-page":"41143","DOI":"10.18632\/oncotarget.17068","volume":"8","author":"G Mittica","year":"2017","unstructured":"Mittica G, Senetta R, Scotto G, Aglietta M, Maggiorotto F, Ghisoni E, et al. Androgen receptor status predicts development of brain metastases in ovarian cancers. Oncotarget. 2017;8(25):41143\u201353.","journal-title":"Oncotarget."},{"key":"655_CR15","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1186\/s12885-015-1897-2","volume":"15","author":"A Grogg","year":"2015","unstructured":"Grogg A, Trippel M, Pfaltz K, L\u00e4drach C, Droeser RA, Cihoric N, et al. Androgen receptor status is highly conserved during tumor progression of breast cancer. BMC Cancer. 2015;15:872.","journal-title":"BMC Cancer"},{"key":"655_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1757-2215-3-14","volume":"3","author":"B Nodin","year":"2010","unstructured":"Nodin B, Zendehrokh N, Br\u00e4ndstedt J, Nilsson E, Manjer J, Brennan DJ, et al. Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival. J Ovarian Res. 2010;3:14.","journal-title":"J Ovarian Res"},{"key":"655_CR17","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1186\/1471-2407-14-829","volume":"14","author":"BL Liu","year":"2014","unstructured":"Liu BL, Liu SJ, Baskys A, Cheng H, Han Y, Xie C, et al. Platinum sensitivity and CD133 expression as risk and prognostic predictors of central nervous system metastases in patients with epithelial ovarian cancer. BMC Cancer. 2014;14:829.","journal-title":"BMC Cancer"},{"issue":"5","key":"655_CR18","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/COC.0b013e3181ec5f4b","volume":"34","author":"K Matsuo","year":"2011","unstructured":"Matsuo K, Eno ML, Ahn EH, Shahzad MM, Im DD, Rosenshein NB, et al. Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer. Am J Clin Oncol. 2011;34(5):488\u201393.","journal-title":"Am J Clin Oncol"},{"issue":"9","key":"655_CR19","first-page":"1511","volume":"20","author":"OO Faluyi","year":"2010","unstructured":"Faluyi OO, Gourley C, Smyth JF, Faratian D, Williams AR, Rye T, et al. Higher incidence of isolated brain metastases in ovarian cancer patients with previous early breast cancer. Int J Gynecol Cancer. 2010;20(9):1511\u20137.","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"655_CR20","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/j.1447-0756.2012.01961.x","volume":"39","author":"M Sekine","year":"2013","unstructured":"Sekine M, Yoshihara K, Komata D, Haino K, Nishino K, Tanaka K. Increased incidence of brain metastases in BRCA1-related ovarian cancers. J Obstet Gynaecol Res. 2013;39(1):292\u20136.","journal-title":"J Obstet Gynaecol Res"},{"issue":"3","key":"655_CR21","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s11060-017-2459-z","volume":"133","author":"S Balendran","year":"2017","unstructured":"Balendran S, Liebmann-Reindl S, Berghoff AS, Reischer T, Popitsch N, Geier CB, et al. Next-generation sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations. J Neuro-Oncol. 2017;133(3):469\u201376.","journal-title":"J Neuro-Oncol"},{"issue":"9","key":"655_CR22","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1172\/JCI67228","volume":"123","author":"JY Yang","year":"2013","unstructured":"Yang JY, Yoshihara K, Tanaka K, Hatae M, Masuzaki H, Itamochi H, et al. Predicting time to ovarian carcinoma recurrence using protein markers. J Clin Invest. 2013;123(9):3740\u201350.","journal-title":"J Clin Invest"},{"issue":"17","key":"655_CR23","doi-asserted-by":"publisher","first-page":"29395","DOI":"10.18632\/oncotarget.12561","volume":"8","author":"H Zhu","year":"2017","unstructured":"Zhu H, Zhu X, Zheng L, Hu X, Sun L. The role of the androgen receptor in ovarian cancer carcinogenesis and its clinical implications. Oncotarget. 2017;8(17):29395\u2013405.","journal-title":"Oncotarget."},{"issue":"3","key":"655_CR24","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s10549-010-0761-y","volume":"124","author":"I Castellano","year":"2010","unstructured":"Castellano I, Allia E, Accortanzo V, Vandone AM, Chiusa L, Arisio R, et al. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat. 2010;124(3):607\u201317.","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"655_CR25","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1158\/1078-0432.CCR-16-0979","volume":"23","author":"I Bozovic-Spasojevic","year":"2017","unstructured":"Bozovic-Spasojevic I, Zardavas D, Broh\u00e9e S, Ameye L, Fumagalli D, Ades F, et al. The prognostic role of androgen receptor in patients with early-stage breast cancer: a meta-analysis of clinical and gene expression data. Clin Cancer Res. 2017;23(11):2702\u201312.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"655_CR26","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/bjc.2016.16","volume":"114","author":"AM Kamal","year":"2016","unstructured":"Kamal AM, Bulmer JN, DeCruze SB, Stringfellow HF, Martin-Hirsch P, Hapangama DK. Androgen receptors are acquired by healthy postmenopausal endometrial epithelium and their subsequent loss in endometrial cancer is associated with poor survival. Br J Cancer. 2016;114(6):688\u201396.","journal-title":"Br J Cancer"},{"issue":"2","key":"655_CR27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s13577-012-0053-4","volume":"26","author":"A Yoshida","year":"2013","unstructured":"Yoshida A, Okamoto N, Tozawa-Ono A, Koizumi H, Kiguchi K, Ishizuka B, et al. Proteomic analysis of differential protein expression by brain metastases of gynecological malignancies. Hum Cell. 2013;26(2):56\u201366.","journal-title":"Hum Cell"},{"issue":"2","key":"655_CR28","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/neup.12172","volume":"35","author":"H Nafisi","year":"2015","unstructured":"Nafisi H, Cesari M, Karamchandani J, Balasubramaniam G, Keith JL. Metastatic ovarian carcinoma to the brain: an approach to identification and classification for neuropathologists. Neuropathology. 2015;35(2):122\u20139.","journal-title":"Neuropathology."},{"issue":"3B","key":"655_CR29","first-page":"1943","volume":"28","author":"NS Kasprowicz","year":"2008","unstructured":"Kasprowicz NS, Fotopoulou C, Oskay-Ozcelik G, El KK, Boehmer D, Sehouli J. Brain metastases in relapsed epithelial ovarian cancer after chemotherapy with pegylated liposomal doxorubicin. Anticancer Res. 2008;28(3B):1943\u20136.","journal-title":"Anticancer Res"},{"issue":"1","key":"655_CR30","doi-asserted-by":"crossref","first-page":"285","DOI":"10.18632\/oncotarget.12306","volume":"8","author":"K Xu","year":"2017","unstructured":"Xu K, Yang S, Zhao Y. Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis. Oncotarget. 2017;8(1):285\u2013302.","journal-title":"Oncotarget."},{"issue":"6","key":"655_CR31","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"A du Bois","year":"2009","unstructured":"du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115(6):1234\u201344.","journal-title":"Cancer."}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-020-00655-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-020-00655-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-020-00655-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T19:35:50Z","timestamp":1620070550000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-020-00655-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,4]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["655"],"URL":"https:\/\/doi.org\/10.1186\/s13048-020-00655-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-15482\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-15482\/v2","asserted-by":"object"}]},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,4]]},"assertion":[{"value":"25 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was submitted to and approved by the Ethic Institutional Review Board for \u201cBiobanking and use of human tissues for experimental studies\u201d of the Pathology Service of the AOU Citt\u00e0 della Salute e della Scienza (Turin, Italy). The project provided a verbal and not written informed consent from the patients due to the retrospective approach of the study, which did not impact on their treatment. All the cases were anonymously recorded. The Institutional Review Board approved this consent procedure.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}